<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00453440</url>
  </required_header>
  <id_info>
    <org_study_id>CNA109479</org_study_id>
    <nct_id>NCT00453440</nct_id>
  </id_info>
  <brief_title>Prospective Epidemiological Study Of The Prevalence Of HLA-B*5701</brief_title>
  <official_title>Prospective Epidemiological Study of the Prevalence of HLA-B*5701 in HIV-1 Infected UK Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ViiV Healthcare</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>ViiV Healthcare</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a study to determine the prevalence of a genetic marker, HLA-B5701, in the UK
      population. HLA-B*5701 has been strongly associated with the risk of an allergic reaction to
      a HIV medicine, Abacavir. The allergic reaction is known as a hypersensitivity reaction.

      The study is a prospective study inviting HIV-1 positive patients over the age of 18 years to
      participate. Each participant will complete one study visit. They will be asked for details
      of their background including their age, sex, ethnicity, country of origin and parental
      country of origin.

      They will be asked to give two samples to test for the presence of the genetic marker
      HLA-B*5701. The two samples are:

        -  A cheek swab

        -  A blood sample

      In selected centres patients may be asked to provide up to two additional blood samples.
      These samples will be used to help develop and validate new methods of determining HLA-B*5701
      testing.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 20, 2007</start_date>
  <completion_date type="Actual">August 10, 2007</completion_date>
  <primary_completion_date type="Actual">August 10, 2007</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <primary_outcome>
    <measure>Prevalence of HLA-B*5701 in the UK population via central labs</measure>
    <time_frame>2 Hours</time_frame>
    <description>The widespread of HLA-B*5701 applied in the selected area in each participant of the UK population was tested via central labs. The result is summarized here.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Prevalence of HLA-B*5701 in major UK ethnotypes in the study population.</measure>
    <time_frame>2 Hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Description of HLA-B*5701 in the UK population via local labs.</measure>
    <time_frame>2 Hours</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">1502</enrollment>
  <condition>Infection, Human Immunodeficiency Virus</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Cheek swab &amp; blood test</intervention_name>
    <description>Cheek swab &amp; blood test</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  HIV-1 infected patients over 18 years of age

          -  Patient willing &amp; able to understand and provide written informed consent

        Exclusion criteria:
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>ViiV Healthcare</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Woolwich, London</city>
        <state>London</state>
        <zip>SE18 4QH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Birmingham</city>
        <state>Warwickshire</state>
        <zip>B4 6DH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Birmingham</city>
        <zip>WS2 9PS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>London</city>
        <zip>E1 1BB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>London</city>
        <zip>E9 6SR</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>London</city>
        <zip>SE1 7EH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>London</city>
        <zip>SW17 0QT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>London</city>
        <zip>W2 1NY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 28, 2007</study_first_submitted>
  <study_first_submitted_qc>March 28, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 29, 2007</study_first_posted>
  <last_update_submitted>September 9, 2017</last_update_submitted>
  <last_update_submitted_qc>September 9, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 12, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HIV</keyword>
  <keyword>HLA-B*5701</keyword>
  <keyword>Abacavir hypersensitivity reaction</keyword>
  <keyword>HIV Infection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunologic Deficiency Syndromes</mesh_term>
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

